Selective accumulation of T cells according to T-cell receptor V beta gene usage in skin cancer.
Selective accumulation of T cells according to T-cell receptor V beta gene usage in skin cancer.
复制标题
根据皮肤癌中 T 细胞受体 V beta 基因的使用情况，T 细胞选择性积累。
DOI：
10.1111/1523-1747.ep12412288
复制
发表时间：
1994
期刊：
影响因子：
--
通讯作者：
Uyemura,K
中科院分区：
文献类型：
--
作者：
Ohmen,JD;Moy,RL;Zovich,D;Lieberman,A;Wyzykowski,RJ;Sullivan,L;Modlin,RL;Uyemura,K
To investigate whether specific T-cell populations are overrepresented in tumor-infiltrating lymphocytes (TIL) in skin cancer, we determined the T-cell receptor (TCR) diversity in biopsy specimens of basal cell carcinoma and squamous cell carcinoma. Immunostaining of tissue sections indicated that the majority of T cells expressed αβ TCRs. To assess diversity of the TCR β chain, RNA was isolated directly from the tumor specimens and peripheral blood mononuclear cells (PBMC) from the same patient, cDNA was synthesized, and variable (V) β chain gene usage was determined by the polymerase chain reaction (PCR). In each basal cell (n = 11) and squamous cell (n = 7) carcinoma studied, several Vβ families were overrepresented in TIL versus PBMC, in that they accounted for greater than 5% of the repertoire in TIL and were at least 2% higher in TIL than in PBMC. The predominant Vβ gene segments overrepresented in TIL generally differed from individual to individual. Simultaneous comparison of the Vβ repertoire of TIL to that of uninvolved skin and PBMC from the same individual revealed preferential expression of Vβ families within the TIL in three of five basal cell and four of four squamous cell carcinomas. Again, the predominant Vβs differed from individual to individual. Comparison of the TCR repertoire in uninvolved skin versus PBMC did indicate that some Vβ families were over-expressed in the resident T-cell compartment in skin, although the overrepresented families were not constant from individual to individual. These data indicate the selective concentration of T cells bearing specific αβ TCRs in the local immune response to basal cell and squamous cell carcinomas.
